美国ApexBio公司是由哈佛博士后团体于2008年成立，专注于为全球科研工作者定制复杂和不稳定的活性小分子。目前已经积累了6000多种高纯度活性小分子，涉及肿瘤、表观遗传学、神经学、凋亡、氧化性损伤、内分泌学等研究领域。...
订购方式
全国免费服务热线：4006-111-945
邮件订货：sales@fansbio.com
QQ：39198264
地址：广东省广州市天河区车陂路95号瑞星大酒店336房
部分抑制剂产品
| A8882 | THZ1 | CDK7 inhibitor |
| A8815 | SM-164 | cIAP-1, cIAP-2 and XIAP inhibitor |
| A8191 | Nanaomycin A | DNMT3B inhibitor |
| A8802 | (S)-Crizotinib | MTH1 inhibitor |
| A8889 | G-749 | FLT3 inhibitor |
| A1910 | Bromodomain Inhibitor, (+)-JQ1 | BET bromodomain inhibitor |
| A2606 | Epoxomicin | 20S proteasome inhibitor |
| A1901 | Q-VD-Oph | pan-caspase inhibitor |
| A1902 | Z-VAD-FMK | pan-caspase inhibitor |
| A1337 | U0126-EtOH | MEK1/2 inhibitor |
| A1402 | Gemcitabine HCl | inhibits DNA synthesis |
| A1663 | PD98059 | Inhibitor of MKK/MEK. |
| A1723 | Roscovitine (Seliciclib,CYC202) | potent CDK inhibitor |
| A1792 | PD184352 (CI-1040) | selective MEK inhibitor |
| A1805 | Imatinib Mesylate (STI571) | Multi-target kinase inhibitor of abl, c-kit, and PDGFR |
| A1832 | Doxorubicin (Adriamycin) | Antitumor antibiotic agent |
| A1877 | XAV-939 | Tankyrase inhibitor |
| A2067 | PI-103 | PI3K, DNA-PK, and mTOR inhibitor |
| A2133 | Saracatinib (AZD0530) | Dual inhibitor of Src and Abl |
| A2149 | Bosutinib (SKI-606) | potent dual c-Src/Abl inhibitor |
| A2585 | MG-132 | Cell permeable, reversible proteasome inhibitor |
| A2614 | Bortezomib (PS-341) | Cell-permeable proteasome inhibitor |
| A2974 | Foretinib (GSK1363089) | Flt-1, Flt-4, Met, and Ron inhibitor. |
| A2977 | Cabozantinib (XL184, BMS-907351) | c-Met, VEGFR2, and RET inhibitor |
| A3001 | Ibrutinib (PCI-32765) | Bruton's tyrosine kinase (BTK) inhibitor |
| A3002 | Veliparib (ABT-888) | Potent inhibitor of PARP-1 and PARP-2 |
| A3003 | Enzalutamide (MDV3100) | Potent androgen receptor antagonist |
| A3004 | Vemurafenib (PLX4032, RG7204) | Potent and selective inhibitor of BRAF with V600E mutation |
| A3005 | CAL-101 (Idelalisib, GS-1101) | Cell-permeable PI3K inhibitor |
| A3007 | ABT-263 (Navitoclax) | Potent Bcl-2 family inhibitor |
| A3008 | Y-27632 2HCl | p160ROCK inhibitor |
| A3010 | MK-2206 2HCl | Akt inhibitor |
| A3011 | CHIR-99021 (CT99021) HCl | Cell-permeable, ATP-competitive GSK-3 inhibitor |
| A3012 | Ruxolitinib (INCB018424) | Janus kinase inhibitor |
| A3013 | PD0325901 | A selective and non ATP-competitive MEK inhibitor |
| A3014 | BGJ398 (NVP-BGJ398) | FGFR inhibitor |
| A3015 | BKM120 (NVP-BKM120, Buparlisib) | PI3K inhibitor |
| A3016 | PLX-4720 | Potent and selective inhibitor of BRAF with V600E mutation |
| A3017 | Dasatinib | Potent Abl and Src kinases inhibitor |
| A3018 | Trametinib (GSK1120212) | Potent and selective MEK1 and MEK2 inhibitor |
| A3020 | Crizotinib (PF-02341066) | Potent c-MET and ALK inhibitor |
| A3021 | Vismodegib (GDC-0449) | Hedgehog antagonist |
| A3022 | Pazopanib HCl (GW786034 HCl) | Multi-target kinase inhibitor, inhibits VEGFR, PDGFR, and FGFR |
| A3432 | GDC-0941 | orally bioavailable and selective class I PI3K inhibitor |
| A3965 | BI 2536 | PLK1 inhibitor |
| A4005 | RO4929097 | γ secretase inhibitor |
| A4054 | 17-AAG (Tanespimycin) | Potent inhibitor of chaperone protein Hsp90 |
| A4057 | AUY922 (NVP-AUY922) | Hsp90 inhibitor |
| A4084 | Vorinostat (SAHA, MK0683) | Class I and II HDAC inhibitor |
| A4089 | Mocetinostat (MGCD0103) | Class I selective HDAC inhibitor |
| A4110 | Alisertib (MLN8237) | Potent and selective Aurora A Kinase inhibitor |
| A4111 | VX-680 (Tozasertib, MK-0457) | Aurora inhibitor |
| A4112 | Barasertib (AZD1152-HQPA) | Potent and selective Aurora Kinase B inhibitor |
| A4135 | Tofacitinib (CP-690550) Citrate | Potent JAK inhibitor |
| A4137 | AZD1480 | ATP-competitive JAK2 inhibitor |
| A4154 | Olaparib (AZD2281, Ku-0059436) | Potent PARP inhibitor |
| A4156 | Rucaparib (AG-014699,PF-01367338) | Potent PARP inhibitor |
| A4180 | SRT1720 | SIRT1 activator |
| A4194 | Obatoclax Mesylate (GX15-070) | antagonist of Bcl-2 |
| A4211 | Lenalidomide (CC-5013) | Antitumor compound, inhibits angiogenesis |
| A4221 | YM155 (Sepantronium Bromide) | Survivin suppressor, induces apoptosis |
| A4393 | Paclitaxel | Chemotherapy agent |
| A4604 | SP600125 | JNK1/2/3 inhibitor |
| A4605 | KU-55933 (ATM Kinase Inhibitor) | Potent and selective ATM inhibitor |
| A5467 | Ponatinib (AP24534) | pan-BCR-ABL inhibitor |
| A5639 | BIRB 796 (Doramapimod) | Cell pemeable p38 MAP Kinase Inhibitor |
| A5919 | AZD7762 | inhibitor of checkpoint kinases (Chks) |
| A8167 | Rapamycin (Sirolimus) | mTOR inhibitor |
| A8169 | Everolimus (RAD001) | mTOR inhibitor |
| A8171 | Entinostat (MS-275) | HDAC1 and HDAC3 but not HDAC8 inhibitor |
| A8178 | Panobinostat (LBH589) | Broad spectrum HDAC inhibitor |
| A8183 | Trichostatin A (TSA) | HDAC inhibitor |
| A8192 | Staurosporine | potent, cell permeable PKC inhibitor |
| A8193 | ABT-737 | Cell-permeable Bcl-2 inhibitor |
| A8200 | DAPT (GSI-IX) | γ-secretase inhibitor |
| A8207 | Selumetinib (AZD6244) | Potent, selective, and ATP-uncompetitive MEK inhibitor |
| A8214 | AZD8055 | Potent, selective, and ATP-competitive mTOR inhibitor |
| A8217 | ICG-001 | Wnt/β-catenin pathway inhibitor |
| A8219 | Gefitinib (ZD1839) | Selective EGFR inhibitor |
| A8232 | Nilotinib (AMN-107) | Bcr-Abl tyrosine kinase inhibitor |
| A8234 | Erlotinib HCl (OSI-744) | Selective EGFR inhibitor |
| A8236 | Regorafenib (BAY 73-4506) | VEGFR, PDGFR, FGFR, mutant kit, RET, and Raf-1 inhibitor |
| A8245 | Sorafenib Tosylate | Raf kinases and tyrosine kinases inhibitor |
| A8246 | BEZ235 (NVP-BEZ235, Dactolisib) | dual inhibitor of PI3K and mTOR |
| A8247 | Afatinib (BIBW2992) | Irreversible EGFR and HER2 inhibitor |
| A8249 | SB431542 | TGF-βR1 (ALK5) inhibitor |
| A8250 | LY294002 | PI3K inhibitor |
| A8251 | TAE684 (NVP-TAE684) | Potent and selective ALK inhibitor |
| A8252 | Nintedanib (BIBF 1120) | VEGFR, PDGFR, and FGFR inhibitor |
| A8309 | Perifosine (KRX-0401) | AKT inhibitor |
| A8314 | Temsirolimus (CCI-779, NSC 683864) | mTOR inhibitor |
| A8315 | NU7441 (KU-57788) | DNA-PK inhibitor |
| A8316 | Palbociclib (PD-0332991) HCl | Highly selective CDK4/6 inhibitor |
| A8321 | Cisplatin | A broad-spectrum chemotherapeutic agent |
| A8334 | OSI-906 (Linsitinib) | Dual inhibitor of IGF1R and IR |
| A8338 | S3I-201 | STAT3 inhibitor |
| A8340 | Cyclopamine | Smoothened inhibitor |
| A8370 | Axitinib | VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit inhibitor |
| A8546 | R406 | ATP-competitive Syk inhibitor |
| A8548 | Fingolimod (FTY720) HCl | A potent S1P receptor agonist |
| A8553 | Ataluren (PTC124) | selective ribosomal read-through of premature inducer |
| A8555 | Vandetanib (ZD6474) | potent VEGFR2 inhibitor |
| B1045 | Sunitinib Malate | An oral, multi-targeted and small-molecule RTK inhibitor |
| B1285 | SB203580 | A specific p38 MAPK inhibitor |
| B1407 | Dabrafenib (GSK2118436) | mutant BRAFV600 specific inhibitor |
栏目导航
产品目录
联系与订购
- 地址：广州市天河区车陂路95号336
- 邮编：510630
- 电话：4006-111-945
- 传真：4006-111-945转9
- 手机：13760639454
- QQ：3002806734 39198264
- EMAIL： sales@fansbio.com
